Ascendis Pharma AS (ASND) Stock Analysis

Ascendis Pharma AS (ASND) is a publicly traded company in the HEALTHCARE sector. It trades at $218.82, carries a market capitalization of $13.52B, a price-to-earnings ratio of 24.87. This page summarizes the public market data, fundamentals, and frequently asked questions for ASND, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $218.82
• Market Cap: $13.52B
• P/E Ratio: 24.87
• EPS: $8.80
• 52-Week High: $250.74
• 52-Week Low: $160.86

Market Sentiment

Ascendis Pharma AS currently has a Bullish sentiment score of 0.26.

About Ascendis Pharma AS

Ascendis Pharma A/S is a biopharmaceutical innovator based in Hellerup, Denmark, dedicated to creating transformative therapies for significant unmet medical needs in various therapeutic areas, particularly rare diseases and endocrine disorders. Leveraging its proprietary TransCon™ technology platform, the company is actively advancing a promising pipeline of product candidates through rigorous clinical trials. Ascendis is focused not only on developing groundbreaking treatments but also on e...

GNG Research Analysis

GNG Research scores Ascendis Pharma AS (ASND) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for ASND.

Frequently Asked Questions

Does ASND pay dividends?

Ascendis Pharma AS (ASND) does not currently pay a regular dividend.

What is ASND's P/E ratio?

Ascendis Pharma AS has a price-to-earnings (P/E) ratio of 24.87.

What is ASND's market cap?

Ascendis Pharma AS (ASND) has a market capitalization of $13.52B with a current stock price of $218.82.